June 2011, Clovis Oncology ($CLVS @ClovisOncology) entered into a license agreement with Pfizer ($PFE @Pfizer) to obtain exclusive global rights to develop and commercialize rucaparib. The rights are exclusive even as to Pfizer and include the right to grant sublicenses.
Upfront Payment $7.0MM
Milestone 1 $0.4MM, April 2014, for the initiation of ARIEL3 pivotal registration study
Milestone 2.0 $88.5MM for clinical study objectives and regulatory filings, acceptances and approvals
Milestone 2.1 $20.75MM associated with the first approval of NDA (inclusive of $88.5MM value)